{"id":"dexamethasone-ophthalmic-insert","safety":{"commonSideEffects":[{"rate":null,"effect":"Increased intraocular pressure"},{"rate":null,"effect":"Cataract formation (with prolonged use)"},{"rate":null,"effect":"Ocular irritation or discomfort"},{"rate":null,"effect":"Conjunctival hyperemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dexamethasone reduces inflammation by inhibiting phospholipase A2, decreasing prostaglandin and leukotriene production, and suppressing immune cell infiltration and cytokine release. The ophthalmic insert formulation provides sustained, localized delivery of the drug to ocular tissues, maintaining therapeutic levels while minimizing systemic exposure and side effects.","oneSentence":"Dexamethasone is a corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:32:31.951Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammation and pain following ocular surgery"},{"name":"Allergic conjunctivitis"},{"name":"Uveitis"}]},"trialDetails":[{"nctId":"NCT06235567","phase":"PHASE1, PHASE2","title":"Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking","status":"ENROLLING_BY_INVITATION","sponsor":"Maanasa Indaram, MD","startDate":"2025-04-11","conditions":"Keratoconus","enrollment":20},{"nctId":"NCT04977427","phase":"PHASE4","title":"Dextenza vs Prednisolone Acetate After Cataract Surgery for Patients With Diabetes","status":"WITHDRAWN","sponsor":"Baylor Research Institute","startDate":"2021-08-31","conditions":"Cataract Diabetic, Macula Edema","enrollment":""},{"nctId":"NCT05626478","phase":"PHASE4","title":"Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery","status":"COMPLETED","sponsor":"Nicole Fram M.D.","startDate":"2023-06-01","conditions":"Corneal Edema, Corneal Defect, Anterior Chamber Inflammation","enrollment":50},{"nctId":"NCT04371445","phase":"PHASE4","title":"Dextenza in the Post-op Management of Vitreoretinal Surgeries","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2020-06-01","conditions":"Vitreoretinal Surgery, Ocular Inflammation, Post-operative Pain","enrollment":30},{"nctId":"NCT05620901","phase":"EARLY_PHASE1","title":"DEXTENZA in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia","status":"COMPLETED","sponsor":"Lejla Vajzovic, MD, FASRS","startDate":"2023-02-01","conditions":"Vitreoretinopathy, Coats' Disease, Exudative Retinopathy","enrollment":16},{"nctId":"NCT05023304","phase":"PHASE4","title":"In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery","status":"COMPLETED","sponsor":"Vance Thompson Vision","startDate":"2021-08-23","conditions":"Cataract","enrollment":30},{"nctId":"NCT04418999","phase":"EARLY_PHASE1","title":"Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus","status":"COMPLETED","sponsor":"Illinois College of Optometry","startDate":"2020-09-01","conditions":"Keratoconus, Dry Eye, Allergy","enrollment":36},{"nctId":"NCT04527887","phase":"PHASE4","title":"Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)","status":"TERMINATED","sponsor":"Tufts Medical Center","startDate":"2020-09-04","conditions":"Dry Eye","enrollment":54},{"nctId":"NCT04237012","phase":"PHASE4","title":"ACCURATE Study for Subjects With Dry Eyes","status":"COMPLETED","sponsor":"The Eye Centers of Racine and Kenosha","startDate":"2019-12-16","conditions":"Dry Eye Syndromes","enrollment":30},{"nctId":"NCT04667507","phase":"PHASE4","title":"Pharmacokinetics of Aqueous Dexamethasone","status":"COMPLETED","sponsor":"Frank A. Bucci, Jr., M.D.","startDate":"2021-01-01","conditions":"Pharmacokinetics, Aqueous Dexamethasone, Inflammatory Cytokine Response","enrollment":102},{"nctId":"NCT04396990","phase":"PHASE4","title":"The RESTORE Study, A Randomized, Controlled, Masked (Reading Center) Prospective Study","status":"COMPLETED","sponsor":"Vance Thompson Vision","startDate":"2020-06-08","conditions":"Refractive Surgery","enrollment":20},{"nctId":"NCT05814757","phase":"PHASE2","title":"OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2023-05-11","conditions":"Dry Eye Syndromes, Eye Diseases","enrollment":100},{"nctId":"NCT04539548","phase":"PHASE3","title":"A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2020-09-04","conditions":"Cataract","enrollment":65},{"nctId":"NCT04498468","phase":"PHASE4","title":"Safety and Efficacy of Dexamethasone Ophthalmic Insert (Dextenza®) in the Management of Clinically Significant Dry Eye","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2021-03-16","conditions":"Dry Eye","enrollment":77},{"nctId":"NCT04200651","phase":"PHASE4","title":"Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery","status":"TERMINATED","sponsor":"The New York Eye Surgery Center","startDate":"2020-01-13","conditions":"Glaucoma, Cataract","enrollment":25},{"nctId":"NCT04168112","phase":"PHASE4","title":"Intracanalicular Dexamethasone Insert for Post-Corneal Cross-Linking Inflammation and Pain- The LINK Study","status":"COMPLETED","sponsor":"Sight Medical Doctors PLLC","startDate":"2020-02-12","conditions":"Keratoconus, Unstable, Collagen Crosslinking, Postoperative Pain","enrollment":20},{"nctId":"NCT04555694","phase":"PHASE4","title":"Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax","status":"COMPLETED","sponsor":"Thomas Chester, OD","startDate":"2020-10-01","conditions":"Dry Eye","enrollment":30},{"nctId":"NCT04380857","phase":"PHASE4","title":"Assessing Dextenza Insert After SMILE Procedure","status":"COMPLETED","sponsor":"William Wiley, MD","startDate":"2020-06-18","conditions":"Post Procedural Infection","enrollment":20},{"nctId":"NCT05372315","phase":"PHASE4","title":"Efficacy of Dextenza Insert in Upper vs Lower Punctum Following Cataract Surgery With PCIOL.","status":"COMPLETED","sponsor":"Iworks Laser and Vision Center","startDate":"2022-06-15","conditions":"Cataract","enrollment":80},{"nctId":"NCT04464629","phase":"PHASE4","title":"Assessing the Efficacy and Safety of DEXTENZA in Pseudo Phakic Patients Undergoing Gas Bubble Repair and Laser Following Retinal Detachment","status":"TERMINATED","sponsor":"Midwest Eye Institute","startDate":"2020-07-14","conditions":"Retinal Detachment","enrollment":7},{"nctId":"NCT04521140","phase":"PHASE4","title":"Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery","status":"COMPLETED","sponsor":"Nicole Fram M.D.","startDate":"2020-10-16","conditions":"Corneal Edema, Corneal Defect, Corneal Transplant","enrollment":36},{"nctId":"NCT05143281","phase":"PHASE4","title":"The SITE Study - Dexamethasone Ophthalmic Insert In OR on Day of Surgery Versus In-office Post-Op Day 1","status":"COMPLETED","sponsor":"Grene Vision Group","startDate":"2021-12-13","conditions":"Cataract","enrollment":23},{"nctId":"NCT04501367","phase":"PHASE4","title":"Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.","status":"UNKNOWN","sponsor":"Kovach Eye Institute","startDate":"2021-04-27","conditions":"Vitrectomy, Macular Pucker, Retinal Edema","enrollment":60},{"nctId":"NCT04479748","phase":"PHASE4","title":"DEXTENZA Compared to Topical Steroid Therapy Prior to Cataract Surgery in Patients Who Receive Premium Intraocular Lenses","status":"COMPLETED","sponsor":"Prism Vision Group","startDate":"2020-10-01","conditions":"Cataract","enrollment":13},{"nctId":"NCT04839549","phase":"PHASE4","title":"Efficacy and Safety of Dextenza Compared to Topical Fluorometholone in Patients With Ocular Rosacea","status":"WITHDRAWN","sponsor":"Eye Associates of Central Texas","startDate":"2020-06-06","conditions":"Ocular Rosacea","enrollment":""},{"nctId":"NCT04462523","phase":"PHASE4","title":"DEXTENZA for the Treatment of Postoperative Pain and Inflammation Following Vitreo-retinal Surgery","status":"COMPLETED","sponsor":"Patrick R. Oellers, MD","startDate":"2020-01-03","conditions":"Vitreo-Retinal Surgery","enrollment":40},{"nctId":"NCT04316936","phase":"PHASE4","title":"Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery","status":"COMPLETED","sponsor":"Silverstein Eye Centers","startDate":"2019-12-10","conditions":"Cataract Surgery","enrollment":15},{"nctId":"NCT05665270","phase":"PHASE4","title":"A Study for Post op Inflammation After Cataract Surgery","status":"UNKNOWN","sponsor":"Wyse Eyecare","startDate":"2023-01-30","conditions":"Cataract","enrollment":40},{"nctId":"NCT04747977","phase":"PHASE2","title":"To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2021-02-12","conditions":"Dry Eye","enrollment":172},{"nctId":"NCT04563299","phase":"PHASE4","title":"Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections","status":"TERMINATED","sponsor":"Retina Vitreous Associates of Florida","startDate":"2020-12-09","conditions":"Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion","enrollment":10},{"nctId":"NCT04945824","phase":"EARLY_PHASE1","title":"A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects","status":"TERMINATED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2021-06-01","conditions":"Healthy","enrollment":2},{"nctId":"NCT04687800","phase":"PHASE4","title":"Clinical Investigation of the Dextenza 0.4mg Intracanalicular Insert Delivery System Used in Cataract Surgery","status":"TERMINATED","sponsor":"Cathleen McCabe MD","startDate":"2020-12-01","conditions":"Cataract","enrollment":1},{"nctId":"NCT05587231","phase":"PHASE4","title":"Comparison of the Postoperative Use of Dextenza vs a Standard Regimen After PRK","status":"UNKNOWN","sponsor":"Navy Medical Center San Diego","startDate":"2022-10","conditions":"Steroid Ophthalmic Insert","enrollment":60},{"nctId":"NCT04465864","phase":"PHASE4","title":"Investigate, Following Cataract Surgery With IOL in Conjunction With Intracanalicular Dexamethasone Insert","status":"COMPLETED","sponsor":"Wolstan and Goldberg Eye Associates","startDate":"2020-02-10","conditions":"Glaucoma, Primary Open Angle, Cataract","enrollment":40},{"nctId":"NCT04658927","phase":"PHASE4","title":"Dextenza With ILUX for Treatment of MGD","status":"COMPLETED","sponsor":"Warrenville Eyecare","startDate":"2021-01-04","conditions":"Meibomian Gland Dysfunction, Evaporative Dry Eye","enrollment":30},{"nctId":"NCT02688309","phase":"","title":"Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2015-01-13","conditions":"Macular Edema, Fibrosis of the Retina","enrollment":44},{"nctId":"NCT04413253","phase":"PHASE4","title":"Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye Disease","status":"TERMINATED","sponsor":"Eye Surgeons of Indiana","startDate":"2020-08-01","conditions":"Dry Eye Syndromes","enrollment":5},{"nctId":"NCT04413279","phase":"PHASE4","title":"Lipiflow Treatment Alone vs. Lipiflow + Dextenza Treatment for Dry Eye Disease","status":"COMPLETED","sponsor":"Eye Surgeons of Indiana","startDate":"2020-08-01","conditions":"Dry Eye Syndromes","enrollment":20},{"nctId":"NCT04708821","phase":"PHASE4","title":"DEXTENZA Therapy for Treatment of Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Clinical Research Center of Florida","startDate":"2021-04-30","conditions":"Bilateral Conjunctivitis (Disorder)","enrollment":31},{"nctId":"NCT04728646","phase":"PHASE4","title":"Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surface Disease Outcomes","status":"WITHDRAWN","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2021-09","conditions":"Graft Vs Host Disease","enrollment":""},{"nctId":"NCT04911361","phase":"PHASE4","title":"The DEPOT Study (Dry Eye Prescription Options for Therapy)","status":"COMPLETED","sponsor":"Research Insight LLC","startDate":"2021-08-10","conditions":"Dry Eye","enrollment":50},{"nctId":"NCT04563559","phase":"PHASE2, PHASE3","title":"PREFERENTIAL Study","status":"WITHDRAWN","sponsor":"Duke University","startDate":"2020-11","conditions":"Cataract Surgery, Glaucoma Surgery","enrollment":""},{"nctId":"NCT05116345","phase":"PHASE4","title":"DEXTENZA for the Treatment of Pain and Inflammation Following Surgical Trabeculectomy and Ahmed Valve Procedures","status":"UNKNOWN","sponsor":"Brian Jerkins, MD","startDate":"2021-11","conditions":"Glaucoma Following Surgery","enrollment":30},{"nctId":"NCT05100186","phase":"PHASE4","title":"The SITE Study - Dexamethasone Ophthalmic Insert In OR on Day of Surgery Versus In-office Post-Op Day 1","status":"UNKNOWN","sponsor":"Joseph Kavanagh, MD","startDate":"2021-11-01","conditions":"Cataract","enrollment":50},{"nctId":"NCT01666210","phase":"PHASE2","title":"Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2012-10","conditions":"Ocular Inflammation and Pain","enrollment":60},{"nctId":"NCT04050865","phase":"PHASE3","title":"A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2019-08-05","conditions":"Allergic Conjunctivitis","enrollment":96},{"nctId":"NCT04975971","phase":"","title":"A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery","status":"COMPLETED","sponsor":"Nicole Fram M.D.","startDate":"2021-03-09","conditions":"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema","enrollment":25},{"nctId":"NCT04863742","phase":"PHASE4","title":"Evaluation Of Vision Recovery And Comfort Index In Patients With Borderline/Mild Dry Eyes Undergoing FLACS With Premium IOL","status":"UNKNOWN","sponsor":"Sight Medical Doctors PLLC","startDate":"2021-04-26","conditions":"Dry Eye Syndromes","enrollment":30},{"nctId":"NCT04529512","phase":"PHASE4","title":"INtravitreal and Aqueous Dexamethasone Levels After DEXtenza","status":"UNKNOWN","sponsor":"Nathan Steinle","startDate":"2021-03","conditions":"Ocular Disease Requiring Surgery","enrollment":40},{"nctId":"NCT04530864","phase":"PHASE4","title":"Pre-Surgical Ocular Surface Treatment With Intracanalicular Dexamethasone Insert And Effect On Intraocular Lens Measurement Accuracy","status":"UNKNOWN","sponsor":"Prism Vision Group","startDate":"2021-01","conditions":"Dry Eye Disease, Cataract Surgery, Ocular Surface Disease","enrollment":35},{"nctId":"NCT04624035","phase":"NA","title":"Implantable Phakic Lens (IPCL) VS Implantable Collamer Lens","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-10-10","conditions":"Myopia","enrollment":60},{"nctId":"NCT04592081","phase":"PHASE4","title":"Dextenza Within Upper Lid Canaliculus Compared With Lower Lid Canaliculus Following Bilateral Cataract Extraction Surgery With PCIOL.","status":"UNKNOWN","sponsor":"Kerry Assil, MD","startDate":"2020-08-01","conditions":"Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation","enrollment":20},{"nctId":"NCT04571788","phase":"","title":"Treating Rhegmatogenous Retinal Detachment by Foldable Capsular Buckle","status":"UNKNOWN","sponsor":"Aier School of Ophthalmology, Central South University","startDate":"2019-09-01","conditions":"Rhegmatogenous Retinal Detachment, Surgery","enrollment":150},{"nctId":"NCT04549935","phase":"PHASE4","title":"The PRIME Study: A Randomized, Controlled, Prospective Study","status":"RECRUITING","sponsor":"Vance Thompson Vision - MT","startDate":"2020-09-14","conditions":"Patient Preference, Patient Outcomes, Post-Operative Inflammation","enrollment":20},{"nctId":"NCT04426734","phase":"PHASE4","title":"Evaluation of DEXTENZA in the Management of Pain and Inflammation in Patients With Anterior Uveitis Compared to Standard of Care Topical Corticosteroids","status":"UNKNOWN","sponsor":"New England Retina Associates","startDate":"2020-07-01","conditions":"Non-infectious Anterior Uveitis","enrollment":30},{"nctId":"NCT04281862","phase":"PHASE4","title":"DEXTENZA Compared to Topical Prednisolone in Patients Undergoing Bilateral LASIK Surgery","status":"UNKNOWN","sponsor":"Vance Thompson Vision","startDate":"2020-01-23","conditions":"Refractive Surgery","enrollment":20},{"nctId":"NCT04205916","phase":"PHASE4","title":"A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery","status":"RECRUITING","sponsor":"Ophthalmic Consultants of Long Island","startDate":"2019-11-04","conditions":"Patient Preference","enrollment":50},{"nctId":"NCT02089113","phase":"PHASE3","title":"OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2014-04","conditions":"Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation","enrollment":241},{"nctId":"NCT01471054","phase":"PHASE2","title":"Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma","status":"TERMINATED","sponsor":"Arman Mashayekhi","startDate":"2014-04","conditions":"Macular Edema, Cystoid Macular Edema, Uveal Melanoma","enrollment":6},{"nctId":"NCT02049476","phase":"PHASE4","title":"Study of the Effectiveness of Ozurdex for the Control of Uveitis","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2014-01","conditions":"Uveitis, Intermediate, Uveitis, Posterior","enrollment":20},{"nctId":"NCT02468700","phase":"PHASE2","title":"OTX-14-006: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Dry Eye","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2015-01","conditions":"Dry Eye","enrollment":43},{"nctId":"NCT02736175","phase":"PHASE3","title":"OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2015-10","conditions":"Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation","enrollment":438},{"nctId":"NCT01580020","phase":"PHASE4","title":"Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05","conditions":"Retinal Vein Occlusion","enrollment":175},{"nctId":"NCT01396057","phase":"PHASE3","title":"Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-07","conditions":"Visual Impairment, Macular Edema, Branch Retinal Vein Occlusion","enrollment":244},{"nctId":"NCT01297686","phase":"PHASE2, PHASE3","title":"Exercise Versus Corticosteroid Randomized Clinical Trial for Plantar Fasciitis","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-05","conditions":"Fasciitis, Plantar","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DEXTENZA®"],"phase":"marketed","status":"active","brandName":"Dexamethasone Ophthalmic Insert","genericName":"Dexamethasone Ophthalmic Insert","companyName":"The Cleveland Clinic","companyId":"the-cleveland-clinic","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dexamethasone is a corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors. Used for Inflammation and pain following ocular surgery, Allergic conjunctivitis, Uveitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}